Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats

Molecular Therapy

Volumn 16, Issue 9, 2008, Pages 1572-1579

  McCoy, Melissa K ^a   Ruhn, Kelly A ^a   Martinez, Terina N ^a   McAlpine, Fiona E ^a   Blesch, Armin ^b   Tansey, Malú G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; DOMINANT NEGATIVE TUMOR NECROSIS FACTOR; LENTIVIRUS VECTOR; OXIDOPAMINE; TUMOR NECROSIS FACTOR ALPHA; XENP 345;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; EMBRYO; FEMALE; GENE TRANSFER; IN VIVO STUDY; INTRANIGRAL DRUG ADMINISTRATION; MICROGLIA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; SUBSTANTIA NIGRA; VIRAL GENE DELIVERY SYSTEM;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CELL NUCLEUS; CELLS, CULTURED; CYTOPLASM; DEPENDOVIRUS; FEMALE; FORELIMB; GENE THERAPY; GENES, DOMINANT; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; IMMUNOENZYME TECHNIQUES; MALE; NERVE DEGENERATION; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; PROTEIN TRANSPORT; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

LENTIVIRUS; RATTUS; RODENTIA;

EID: 50549103590     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.146     Document Type: Article

References (30)

1. McGeer, PL and McGeer, EG (2004). Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 10 (suppl. 1): S3-S7.
2. Tansey, MG, McCoy, MK and Frank-Cannon, TC (2007). Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208: 1-25.
3. Whitton, PS (2007). Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150: 963-976.
4. Chen, H, Zhang, SM, Hernan, MA, Schwarzschild, MA, Willett, WC, Colditz, GA et al. (2003). Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60: 1059-1064.
5. Mogi, M, Harada, M, Riederer, P, Narabayashi, H, Fujita, K and Nagatsu, T (1994). Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165: 208-210.
6. Sriram, K, Matheson, JM, Benkovic, SA, Miller, DB, Luster, MI and O'Callaghan, JP (2002). Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease. FASEB J 16: 1474-1476.
7. Mogi, M, Togari, A, Tanaka, K, Ogawa, N, Ichinose, H and Nagatsu, T (1999). Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction. Neurosci Lett 268 101-104.
8. McCoy, MK, Martinez, TN, Ruhn, KA, Szymkowski, DE, Smith, CG, Botterman, BR et al. (2006). Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 26: 9365-9375.
9. Steed, PM, Tansey, MG, Zalevsky, J, Zhukovsky, EA, Desjarlais, JR, Szymkowski, DE et al. (2003). Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301 1895-1898.
10. Zalevsky, J, Secher, T, Ezhevsky, SA, Janot, L, Steed, PM, O'Brien, C et al. (2007). Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 179: 1872-1883.
11. Aggarwal, BB, Samanta, A, and Feldmann, M (2000). TNFα. In: Oppenheim, JJ and Feldmann, M (eds.). Cytokine Reference. Academic Press: London, pp. 414-434.
12. Choi, HK, Won, LA, Kontur, PJ, Hammond, DN, Fox, AP, Wainer, BH et al. (1991). Immortalization of embryonic mesencephalic dopaminergic neurons by somatic cell fusion. Brain Res 552: 67-76.
13. Hohmann, HP, Remy, R, Poschl, B and van Loon, AP (1990). Tumor necrosis factors-alpha and -beta bind to the same two types of tumor necrosis factor receptors and maximally activate the transcription factor NF-kappa B at low receptor occupancy and within minutes after receptor binding. J Biol Chem 265: 15183-15188.
14. Rosenblad, C, Grønborg, M, Hansen, C, Blom, N, Meyer, M, Johansen, J et al. (2000). In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin. Mol Cell Neurosci 15: 199-214.
15. Georgievska, B, Kirik, D and Bjorklund, A (2004). Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J Neurosci 24: 6437-6445.
16. Kirik, D, Rosenblad, C and Bjorklund, A (1998). Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152: 259-277.
17. Woodlee, MT, Asseo-Garcia, AM, Zhao, X, Liu, SJ, Jones, TA, Schallert, T (2005). Testing forelimb placing "across the midline" reveals distinct, lesion-dependent patterns of recovery in rats. Exp Neurol 191: 310-317.
18. Bensadoun, J-C, Deglon, N, Tseng, JL, Ridet, J-L, Zum, AD and Aebischer, P (2000). Lentiviral vectors as a gene delivery system in the mouse midbrain: Cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp Neurol 164: 15-24.
19. Georgievska, B, Kirik, D, Rosenblad, C, Lundberg, C and Bjorklund, A (2002). Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13: 75-82.
20. Dowd, E, Monville, C, Torres, EM, Wong, LF, Azzouz, M, Mazarakis, ND et al. Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. Eur J Neurosci 22: 2587-2595.
21. Scheinfeld, N (2004). A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 15: 280-294.
22. Tweedie, D, Sambamurti, K and Greig, NH (2007). TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: New drug candidates and targets. Curr Alzheimer Res 4: 378-385.
23. William, H and Robinson MCGLWM (2001). Demyelinating and neurologic events reported in association with tumor necrosis factor? Antagonism: by what mechanisms could tumor necrosis factor? Antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44: 1977-1983.
24. van Oosten, BW, Barkhof, F, Truyen, L, Boringa, JB, Bertelsmann, FW, von Blomberg, BM et al. (1996). Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531-1534.
25. Stellwagen, D and Malenka, RC (2006). Synaptic scaling mediated by glial TNF-alpha. Nature 440: 1054-1059.
26. Pfeifer, A, Ikawa, M, Dayn, Y and Verma, IM (2002). Transgenesis by lentiviral vectors: Lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad Sci USA 99 2140-2145.
27. Taylor, L, Jones, L, Tuszynski, MH and Blesch, A (2006). Neurotrophin-3 gradients established by lentiviral gene delivery promote short-distance axonal bridging beyond cellular grafts in the injured spinal cord. J Neurosci 26: 9713-9721.
28. Liu, B, Du, L and Hong, JS (2000). Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 293 607-617.
29. West, MJ, Slomianka, L and Gundersen, HJ (1991). Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231: 482-497.
30. German, DC and Manaye, KF (1993). Midbrain dopaminergic neurons (nuclei A8, A9, and A10): Three-dimensional reconstruction in the rat. J Comp Neurol 331: 297-309.